Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

NCT04305327 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Early terminated due to difficulty recruiting participants

Conditions

Psoriasis

Interventions

DRUG: Brodalumab
DRUG: Ustekinumab
DRUG: Placebo

Sponsor

LEO Pharma